160
Participants
Start Date
August 31, 2009
Primary Completion Date
August 31, 2019
Study Completion Date
August 31, 2019
Needle core biopsies of liver metastasis
No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
University Hospital Leuven, Leuven
Hôpital Sacré-Coeur, Montreal
The Moncton Hospital, Moncton
Dr. Georges L. Dumont University Hospital, Moncton
Sunnybrook Health Sciences Centre, Toronto
Mount Sinai Hospital, Toronto
Hôpital Charles Lemoyne, Greenfield Park
Hôpital Maisonneuve-Rosemont, Montreal
Hôpital Notre-Dame, Montreal
Hôpital Saint-Luc, Montreal
Royal Victoria Hospital, Montreal
Jewish General Hospital, Montreal
St-Mary's Hospital, Montreal
McGill University Health Centre, Montreal
Hôtel-Dieu du Québec, Québec
Collaborators (1)
Exactis Innovation
OTHER
Terry Fox Research Institute
OTHER
Fonds de la Recherche en Santé du Québec
OTHER_GOV
Jewish General Hospital
OTHER